Pharma demand remains strong, but Emergency Medicine destocking and Beauty execution continue to suppress earnings.
| Quarter | Q2 FY26 |
|---|---|
| Call date | 2026-07-30 |
| Length | 56 minutes |
| EPS | $1.42 |
| EPS consensus | $1.34 |
| Revenue | $1.0B |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q1 FY26 · Q2 FY25
All ATR earnings · Back to ATR overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.